Presentations will feature insights into optimizing VP1 ratios and the development of a high-yielding scalable Sf9-baculovirus platform for AAV production. Lexeo is developing therapies targeting ...

VectorY Therapeutics (VectorY), a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced that it will have four feat ...

“We are particularly proud of our exciting preclinical data in amyotrophic lateral sclerosis (ALS), Huntington’s disease, and of our optimized AAV & baculovirus production process for one-time ...

Research highlights AAV manufacturing optimization via Lexeo’s Sf9-baculovirus processNEW YORK, May 01, 2025 (GLOBE NEWSWIRE) ...

Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their research efforts around the adeno-associated virus (AAV) vectors used ...

“The data being presented at ASGCT underscore the strength of our industry-leading capabilities in AAV manufacturing with high yield and high quality,” said José Manuel Otero, Chief Technical ...